Aijie Qi

Title: Aijie Qi - Innovator in Cancer Treatment

Introduction

Aijie Qi, located in Beijing, China, is recognized for his significant contribution to cancer treatment through innovative methods in cellular therapy. He holds one patent that focuses on a groundbreaking approach to harnessing natural killer (NK) cells for the treatment of cancer, particularly colorectal cancer.

Latest Patents

Aijie Qi's notable patent is titled "Preparation method of NK cells and use thereof in the treatment of cancer." This patent describes an advanced method for preparing NK cells and their application in cancer treatment. The disclosure highlights a pharmaceutical composition that combines NK cells with a monoclonal antibody of CD105, illustrating its potential effectiveness and promising application in addressing colorectal cancer.

Career Highlights

Currently, Aijie Qi works at Sino United (Beijing) Biomedical Technology Co., Ltd., where he contributes his expertise in biomedical innovation and research. His work focuses on developing therapies that leverage the immune system, showcasing his commitment to advancing healthcare and improving patient outcomes.

Collaborations

In his professional journey, Aijie Qi collaborates closely with esteemed coworkers such as Shaobo Li and Ailei Qi. Together, they work towards common goals in research and development, driving forward the mission of their company and the field of cancer treatment.

Conclusion

Aijie Qi exemplifies the innovative spirit necessary for advancing therapeutic options in the battle against cancer. His contributions, particularly through the patent on NK cells, recognize the potential of cellular therapies in addressing complex health challenges. Through his ongoing work at Sino United (Beijing) Biomedical Technology Co., Ltd., Aijie Qi continues to pave the way for future advancements in biomedical technologies.